** Shares of drug developer Plus Therapeutics PSTV.O more than double to 38 cents
** Co says the U.S. FDA has cleared its application to begin human trials for its experimental brain cancer therapy
** The trial is funded by a $3 million research grant from the U.S. Department of Defense, co says
** The early-stage trial is aimed to determine the maximum tolerated dose safety and tolerability of the therapy called Reyobiq in pediatric patients aged six to 21 years
** The company is testing the therapy to treat aggressive brain tumors called high-grade glioma and ependymoma
** Including session moves, stock down 68.1% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。